BR112019007843A2 - métodos para prevenção de eventos cardiovascu-lares através da redução de proteína pró-proteina convertase subtilisina/quexina tipo 9 (pcsk9) - Google Patents
métodos para prevenção de eventos cardiovascu-lares através da redução de proteína pró-proteina convertase subtilisina/quexina tipo 9 (pcsk9)Info
- Publication number
- BR112019007843A2 BR112019007843A2 BR112019007843A BR112019007843A BR112019007843A2 BR 112019007843 A2 BR112019007843 A2 BR 112019007843A2 BR 112019007843 A BR112019007843 A BR 112019007843A BR 112019007843 A BR112019007843 A BR 112019007843A BR 112019007843 A2 BR112019007843 A2 BR 112019007843A2
- Authority
- BR
- Brazil
- Prior art keywords
- protein
- individual
- atherosclerotic cardiovascular
- pcsk9
- subtilisin
- Prior art date
Links
- 102000006437 Proprotein Convertases Human genes 0.000 title 1
- 108010044159 Proprotein Convertases Proteins 0.000 title 1
- 108090000787 Subtilisin Proteins 0.000 title 1
- 230000007211 cardiovascular event Effects 0.000 title 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 4
- 201000001320 Atherosclerosis Diseases 0.000 abstract 4
- 108010028554 LDL Cholesterol Proteins 0.000 abstract 1
- 230000003143 atherosclerotic effect Effects 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
a presente invenção refere-se a um método de redução do colesterol de lipoproteína de baixa densidade ou prevenção de um evento cardíaco em um indivíduo que tem doença cardiovascular ate-rosclerótica ou equivalente de risco cardiovascular aterosclerótico, envolvendo a administração ao indivíduo de uma quantidade profilaticamente eficaz de um agente de rnai. igualmente, um método de prevenção do desenvolvimento de doença cardiovascular aterosclerótica em um indivíduo envolvendo a administração ao indivíduo de uma quantidade profilaticamente eficaz de um agente de rnai. além disso, um método de tratamento de um indivíduo que tem doença cardiovascular aterosclerótica ou que está em equivalente de risco da doença cardiovascular aterosclerótica envolvendo a administração ao indivíduo de uma quantidade terapeuticamente eficaz de um agente de rnai.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662409816P | 2016-10-18 | 2016-10-18 | |
US201662422028P | 2016-11-14 | 2016-11-14 | |
US201762472525P | 2017-03-16 | 2017-03-16 | |
US201762550426P | 2017-08-25 | 2017-08-25 | |
PCT/US2017/057218 WO2018075658A1 (en) | 2016-10-18 | 2017-10-18 | Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019007843A2 true BR112019007843A2 (pt) | 2019-10-01 |
Family
ID=60388127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019007843A BR112019007843A2 (pt) | 2016-10-18 | 2017-10-18 | métodos para prevenção de eventos cardiovascu-lares através da redução de proteína pró-proteina convertase subtilisina/quexina tipo 9 (pcsk9) |
Country Status (12)
Country | Link |
---|---|
US (2) | US20180104360A1 (pt) |
EP (1) | EP3529360B1 (pt) |
JP (2) | JP7181881B2 (pt) |
KR (2) | KR20190077411A (pt) |
CN (1) | CN110088283A (pt) |
AU (2) | AU2017346879B2 (pt) |
BR (1) | BR112019007843A2 (pt) |
CA (1) | CA3042423A1 (pt) |
CL (1) | CL2019001047A1 (pt) |
IL (1) | IL266066A (pt) |
MX (1) | MX2019004573A (pt) |
WO (1) | WO2018075658A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108348541A (zh) | 2015-08-25 | 2018-07-31 | 阿尔尼拉姆医药品有限公司 | 用于治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物 |
US11492620B2 (en) | 2017-12-01 | 2022-11-08 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof |
CN110997917B (zh) | 2017-12-01 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
WO2019128611A1 (en) | 2017-12-29 | 2019-07-04 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
US11918600B2 (en) | 2018-08-21 | 2024-03-05 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof |
WO2020063198A1 (zh) | 2018-09-30 | 2020-04-02 | 苏州瑞博生物技术有限公司 | 一种siRNA缀合物及其制备方法和用途 |
JP2022533841A (ja) * | 2019-05-22 | 2022-07-26 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
CA3167849A1 (en) | 2020-03-16 | 2021-09-23 | Daniel Mitchell | Antagonist of pcsk9 |
WO2024061157A1 (en) * | 2022-09-19 | 2024-03-28 | Kylonova (Xiamen) Biopharma Co., Ltd. | Carbohydrate-oligonucleotide conjugates, pharmaceutical compositions, and therapeutic applications |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ587616A (en) * | 2006-05-11 | 2012-03-30 | Alnylam Pharmaceuticals Inc | Compositions and methods for inhibiting expression of the pcsk9 gene |
US10125369B2 (en) * | 2012-12-05 | 2018-11-13 | Alnylam Pharmaceuticals, Inc. | PCSK9 iRNA compositions and methods of use thereof |
-
2017
- 2017-10-18 EP EP17800976.7A patent/EP3529360B1/en active Active
- 2017-10-18 BR BR112019007843A patent/BR112019007843A2/pt unknown
- 2017-10-18 KR KR1020197014059A patent/KR20190077411A/ko not_active Application Discontinuation
- 2017-10-18 CN CN201780077941.7A patent/CN110088283A/zh active Pending
- 2017-10-18 MX MX2019004573A patent/MX2019004573A/es unknown
- 2017-10-18 CA CA3042423A patent/CA3042423A1/en active Pending
- 2017-10-18 JP JP2019542356A patent/JP7181881B2/ja active Active
- 2017-10-18 KR KR1020247014347A patent/KR20240067272A/ko active Search and Examination
- 2017-10-18 US US15/787,405 patent/US20180104360A1/en not_active Abandoned
- 2017-10-18 AU AU2017346879A patent/AU2017346879B2/en active Active
- 2017-10-18 WO PCT/US2017/057218 patent/WO2018075658A1/en active Application Filing
-
2019
- 2019-04-16 IL IL266066A patent/IL266066A/en unknown
- 2019-04-17 CL CL2019001047A patent/CL2019001047A1/es unknown
-
2020
- 2020-06-22 US US16/908,517 patent/US20210093736A1/en active Pending
-
2022
- 2022-04-19 JP JP2022068684A patent/JP2022109948A/ja active Pending
-
2023
- 2023-11-09 AU AU2023263519A patent/AU2023263519A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2023263519A1 (en) | 2023-12-07 |
KR20240067272A (ko) | 2024-05-16 |
KR20190077411A (ko) | 2019-07-03 |
MX2019004573A (es) | 2019-10-07 |
EP3529360B1 (en) | 2024-04-17 |
AU2017346879B2 (en) | 2023-11-30 |
CL2019001047A1 (es) | 2020-05-08 |
AU2017346879A1 (en) | 2019-05-23 |
US20210093736A1 (en) | 2021-04-01 |
JP2022109948A (ja) | 2022-07-28 |
JP2019531357A (ja) | 2019-10-31 |
US20180104360A1 (en) | 2018-04-19 |
CA3042423A1 (en) | 2018-04-26 |
CN110088283A (zh) | 2019-08-02 |
WO2018075658A1 (en) | 2018-04-26 |
IL266066A (en) | 2019-06-30 |
JP7181881B2 (ja) | 2022-12-01 |
EP3529360A1 (en) | 2019-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019007843A2 (pt) | métodos para prevenção de eventos cardiovascu-lares através da redução de proteína pró-proteina convertase subtilisina/quexina tipo 9 (pcsk9) | |
BR112017007975A2 (pt) | composições e métodos para o tratamento de disfunção das glândulas meibomianas | |
BR112018069732A2 (pt) | métodos para prevenir, tratar, reverter e/ou retardar angiogênese em um sujeito mamífero, para tratar um sujeito que sofre de uma doença ou condição angiogênica ocular e para inibir angiogênese do tumor | |
CR20120638A (es) | Métodos de terapia combinada para tratar enfermedades proliferativas | |
MX2016011975A (es) | Metodos para reducir el riesgo cardiovascular. | |
BR112015000174A2 (pt) | método para o tratamento da artrite | |
BR112014008731A2 (pt) | tratamento de esclerose múltipla com combinação de laquinimode e fingolimode | |
BR112015017101A2 (pt) | composições de tratamento compreendendo microcápsulas, aminas primárias ou secundárias e sequestrantes de formaldeído | |
BR112017004704A2 (pt) | composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo | |
BR112018006445A2 (pt) | métodos para tratar distrofia muscular | |
MX2014013523A (es) | Preparaciones de agentes terapeuticos hidrofobos, metodos de elaboracion y uso de los mismos. | |
BR112015000321A2 (pt) | formulações de laquinimod sem agente alcalinizante | |
EA201791993A1 (ru) | Способы лечения протеинопатий | |
BR112018013833A2 (pt) | métodos de administração de hepcidina | |
PH12019500422A1 (en) | Methods and composition for the prediction of the activity of enzastaurin | |
BR112017018328A2 (pt) | anticorpo de ligação ao tfpi, método para produzir e composição compreendendo o mesmo | |
BR112015018360A2 (pt) | terapia de combinação para o tratamento de pneumonia nosocomial | |
BR112019009726A2 (pt) | terapias combinadas para aterosclerose, incluindo doença cardiovascular aterosclerótica | |
BR112019002458A2 (pt) | composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos | |
BR112016015997A2 (pt) | ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas? | |
BR112014000773A8 (pt) | Composições de nicotinamida e uso terapêutico das mesmas | |
BR112017007066A2 (pt) | composições e métodos para melhorar a mobilidade ou a atividade, ou tratar a debilidade | |
BR112017008805A2 (pt) | tratamento de córnea usando laminina | |
BR112019008241A2 (pt) | tratamento do prurigo nodular | |
BR112015019564A2 (pt) | tratamento de esclerose múltipla com laquinimod |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122022026853-6 PROTOCOLO 870220122961 EM 28/12/2022 14:30. |
|
B25A | Requested transfer of rights approved |
Owner name: NOVARTIS AG (CH) |